{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:04:16Z","timestamp":1790831056677,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The presence of polymorphonuclear neutrophils (PMNs) in the tumor microenvironment is associated with lower survival rates for cancer patients. Presumably due to the immunosuppressive activity of neutrophils (also known as Myeloid-Derived Suppressor Cell (MDSC) activity). We investigated whether this MDSC activity shows any selectivity in suppressing specific lymphocyte subsets. Our data show that CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, both naive and memory fractions, are sensitive to PMN-MDSC activity. Similarly, regulatory T cells, believed to play an important immunosuppressive function themselves, were affected too. In contrast, the more innate-like \u03b3\u03b4 T cells and Natural Killer (NK) cells were left intact. Our data suggest that Chimeric Antigen Receptor (CAR)-NK and \u03b3\u03b4 CAR-T cell immunotherapy may be less susceptible to PMN-MDSC activity. Therefore, using such MDSC-resistant innate cells as cellular products may be of advantage over the common \u03b1\u03b2 CAR-T cell therapies. Additionally, further deciphering the exact mechanisms by which neutrophils suppress \u03b1\u03b2 T cells could lead to improved T cell immunotherapies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1977867","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:47:05Z","timestamp":1790830025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophils suppress adaptive \u03b1\u03b2 T cells but not the innate \u03b3\u03b4 T cells and natural killer cells"],"prefix":"10.3389","volume":"17","author":[{"given":"Angela A.F.","family":"Gankema","sequence":"first","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"van Oosterom","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon C.","family":"Slot","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line I.","family":"Mahieu","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatia","family":"Rontogianni","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Verkerk","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Amsen","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"van Bruggen","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[{"name":"Sanquin Research, University of Amsterdam","place":["Amsterdam, Netherlands"]},{"name":"Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children\u2019s Hospital, Amsterdam University Medical Center (Amsterdam UMC), University of Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011184","article-title":"Estimation of eligibility for and response to CAR-T therapy in the United States","volume":"8","author":"Haslam","year":"2024","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1186\/s13045-025-01677-3","article-title":"CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting","volume":"18","author":"Kong","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","unstructured":"CAR-T cell therapy market 2026: Approved products, pipeline & licensing opportunities\n          \n          \n          \n          2026"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.3390\/biom15101407","article-title":"Advancing CAR-T therapy for solid tumors: From barriers to clinical progress","volume":"15","author":"Smirnov","year":"2025","journal-title":"Biomolecules"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1141","article-title":"Engineering chimeric antigen receptor T cells for solid tumour therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Clin Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101668","article-title":"Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells","author":"Tumino","year":"2022","journal-title":"Semin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1200941","article-title":"Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy","volume":"14","author":"Shafqat","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072024","article-title":"The glioma immune landscape: A double-edged sword for treatment regimens","volume":"15","author":"Mahajan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638841","article-title":"Interaction between MDSC and NK cells in solid and hematological malignancies: Impact on HSCT","volume":"12","author":"Tumino","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transduction Targeted Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Institute"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2024.100604","article-title":"Prognostic significance of neutrophil to lymphocyte ratio (NLR) in oral squamous cell carcinoma","volume":"11","author":"Thayalan","year":"2024","journal-title":"Oral Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.07.022","article-title":"FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets","volume":"490","author":"Saleh","year":"2020","journal-title":"Cancer Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S284941","article-title":"Studying neutrophil function in vitro: Cell models and environmental factors","volume":"14","author":"Blanter","year":"2021","journal-title":"J Inflammation Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019031609","article-title":"Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair","volume":"3","author":"Aarts","year":"2019","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-032-00749-0","volume-title":"Cancer Immunology and Genetics: An Interdisciplinary Approach","author":"Rezaei","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343664","article-title":"Neutrophils suppress \u03b3\u03b4 T-cell function","volume":"44","author":"Sabbione","year":"2014","journal-title":"Eur J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01271","article-title":"Myeloid-derived suppressor cells specifically suppress iFn- \u03b3 production and antitumor cytotoxic activity of V \u03b4 2 T cells","volume":"9","author":"Sacchi","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101380","article-title":"Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors","volume":"5","author":"Pettinella","year":"2024","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/eji.70107","article-title":"Isolation of pure stable human Treg cells based on expression of GPA33","volume":"56","author":"Morgana","year":"2026","journal-title":"Eur J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901250","article-title":"GPA33: A marker to identify stable human regulatory T cells","volume":"204","author":"Opstelten","year":"2020","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.celrep.2018.05.082","article-title":"Neutrophils kill antibody-opsonized cancer cells by trogoptosis","volume":"23","author":"Matlung","year":"2018","journal-title":"Cell Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.06.017","article-title":"Resident memory T cells and cancer","volume":"57","author":"Gavil","year":"2024","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.3390\/ijms25137346","article-title":"Complex role of regulatory T cells (Tregs) in the tumor microenvironment: Their molecular mechanisms and bidirectional effects on cancer progression","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1797-6","article-title":"Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic","volume":"65","author":"Majchrzak","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218011","article-title":"CD4 T helper cell subsets and related human immunological disorders","volume":"21","author":"Zhu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3390\/cancers15061650","article-title":"Role and potential of different T helper cell subsets in adoptive cell therapy","volume":"15","author":"Andreu-Sanz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/eji.202451075","article-title":"Function and spatial organization of tumor-invasive human \u03b3\u03b4 T cells\u2014what do we know","volume":"55","author":"Wistuba-Hamprecht","year":"2025","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01365","article-title":"The conventional nature of non-MHC-restricted T cells","volume":"9","author":"Lepore","year":"2018","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/JLB.3A1020-630RR","article-title":"Activation of human \u03b3\u03b4 T cells and NK cells by Staphylococcal enterotoxins requires both monocytes and conventional T cells","volume":"111","author":"Mata Forsberg","year":"2022","journal-title":"J Leukoc Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4342","article-title":"Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV","volume":"170","author":"Kuijpers","year":"2003","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002040","article-title":"Human neutrophil clearance of bacterial pathogens triggers anti-microbial \u03b3\u03b4 T cell responses in early infection","volume":"7","author":"Davey","year":"2011","journal-title":"PloS Pathog"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-30621-4","article-title":"TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-\u03baB pathway","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70062","article-title":"TNF production or TNFR2 expression characterize distinct states of regulatory T cells that cooperate in Treg expansion in cancer and chronic inflammation","volume":"55","author":"Tucci","year":"2025","journal-title":"Eur J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1696587","article-title":"A novel TNFR2 agonist peptide for the expansion of CD4+Foxp3+ regulatory T cells","volume":"16","author":"Liao","year":"2025","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-00271-w","article-title":"Stable human regulatory T cells switch to glycolysis following TNF receptor 2 costimulation","volume":"2","author":"de Kivit","year":"2020","journal-title":"Nat Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881166","article-title":"TNFR2 costimulation differentially impacts regulatory and conventional CD4+ T-cell metabolism","volume":"13","author":"Mensink","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1977867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:47:12Z","timestamp":1790830032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1977867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1977867"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1977867","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1977867"}}